TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features

Modern Pathology

Volumn 23, Issue 10, 2010, Pages 1325-1333

  Fine, Samson W ^a   Gopalan, Anuradha ^a   Leversha, Margaret A ^a   Al Ahmadie, Hikmat A ^a   Tickoo, Satish K ^a   Zhou, Qin ^a   Satagopan, Jaya M ^a   Scardino, Peter T ^a   Gerald, William L ^a   Reuter, Victor E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ERG; Fusion; Gleason score; Morphology; Prostate cancer; TMPRSS2

Indexed keywords

ARTICLE; CANCER GRADING; COPY NUMBER VARIATION; ERG GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE FUSION; GENE TRANSLOCATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TMPRSS2 GENE;

ADENOCARCINOMA; GENE DOSAGE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 77957604323     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.120     Document Type: Article

References (43)

1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
2. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2007;27: 253-263.
3. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26: 4596-4599.
4. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2- ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31: 882-888.
5. Gopalan A, Leversha M, Satagopan J, et al. TMPRSS2- ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69: 1400-1406.
6. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007;20:467-473.
7. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009;15:4706-4711.
8. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-8341.
9. Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008;14:3395-3400.
10. Han B, Mehra R, Suleman K, et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 2009;22:1176-1185.
11. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol 2009;22:359-365.
12. Mosquera JM, Perner S, Demichelis F, et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol 2007;212:91-101.
13. Tu JJ, Rohan S, Kao J, et al. Gene fusion between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissue. Mod Pathol 2007;20:921-928.
14. Soller MJ, Isaksson M, Elfving P, et al. Confirmation of the high frequency of TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006;45: 717-719.
15. Albadine R, Latour M, Toubaji A, et al. TMPRSS2-ERG gene fusion in minute (minimal) prostatic adenocarcinoma. Mod Pathol 2009;22:1415-1422.
16. Darnel AD, LaFargue CJ, Vollmer RT, et al. TMPRSS2- ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Bio Ther 2009;8:125-130.
17. Nam RK, Sugar L, Yang W, et al. Expression of TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-1695.
18. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2-ERG fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238-1243.
19. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008;21:1451-1460.
20. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostatic adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007;67: 7991-7995.
21. Wang J, Cai Y, Ren C, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-8351.
22. Leversha MA. Mapping of genomic clones by fluorescence in situ hybridization. Methods Mol Biol 2001; 175:109-127.
23. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 1974;111:58-64.
24. Gleason DF. Histologic grading and staging of prostatic carcinoma In: Tannenbaum M (ed). Urologic Pathology: The Prostate. Lea and Febiger: Philadelphia, 1977, pp 171-198.
25. Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-292.
26. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1642-1645.
27. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000;124:995-1000.
28. Epstein JI, Amin A, Boccon-Gibod L, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005;216:34-63.
29. Guimaraes MS, Quintal MM, Meirelles LR, et al. Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy. Int Braz J Urol 2008;34:23-29.
30. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173: 1938-1942.
31. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23:7005-7012.
32. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent expression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-3852.
33. Epstein JI, Allsbrook Jr WC, Amin MB, et al. The 2005 International Society of Urologic Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228-1242.
34. Latour M, Amin MB, Billis A, et al. Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol 2008;32:1532-1539.
35. McNeal JE, Yemoto CEM. Spread of adenocarcinoma within prostatic ducts and acini. Am J Surg Pathol 1996;20:802-814.
36. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol 2006;19:1528-1535.
37. Baisden BL, Kahane H, Epstein JI. Perineural invasion, mucinous fibroplasia, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy. Am J Surg Pathol 1999;23:918-924.
38. Lotan TL, Epstein JI. Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol 2009;40:471-477.
39. Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med 2000;124:98-107.
40. Varma M, Lee MW, Tamboli P, et al. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens: a study of 250 consecutive cases in a routine surgical pathology practice. Arch Pathol Lab Med 2002;126:554-561.
41. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 2004;17:307-315.
42. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol 2007;60: 35-42.
43. Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol 2008;32:468-472.